borderline significancep = 0.05
The pooled estimate showed borderline significance ( Figure 2 ; p = 0.05; MD 5.19, 95% CI 0.09 to 10.29; I 2 = 65%).
The pooled estimate showed borderline significance ( Figure 2 ; p = 0.05; MD 5.19, 95% CI 0.09 to 10.29; I 2 = 65%).
Excluding this study reduced I 2 to 0% in the desloratadine subgroup, where the effect became borderline significant ( p = 0.05; MD 5.04, 95% CI –0.05 to 10.12), and yielded a significant overall benefit in favor of the combination therapy with low heterogeneity ( p = 0.005; MD 6.71, 95% CI 2.03 to 11.39; I 2 = 12%).
The desloratadine subgroup showed no effect ( Figure 2 ; p = 0.96; OR 0.99, 95% CI 0.55 to 1.76; I 2 = 0%), and the levocetirizine subgroup likewise failed to reach significance ( Figure 2 ; p = 0.20; OR 0.52, 95% CI 0.19 to 1.42; I 2 = 0%).
Although this result did not reach statistical significance, it showed a clear trend in favor of combination therapy.
Although this result did not reach statistical significance, it showed a clear trend in favor of combination therapy.